683240-52-0

Usage

Structure

Contains a benzimidazole ring with a bromine atom and a trifluoromethyl group attached to it.

Potential Pharmaceutical Applications

Could be utilized in the development of new drugs.

Biological Activities

May exhibit a range of biological activities.

Medicinal Chemistry Applications

Used as a building block in medicinal chemistry.
Synthesis of novel therapeutic agents.

Interest for Further Research

Unique structural properties make it an interesting target for further research and development in organic chemistry.

Upstream product

• 113170-72-2 3-bromo-5-(trifluoromethyl)benzene-1,2-diamine 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 683241-24-9 6-(trifluoromethyl)-4-(3,4,5-trifluorophenyl)-1,3-dihydro-2H-benzimidazol-2-one 
• 683244-29-3 (6-{3-methyl-4-[6-trifluoromethyl-4-(3,4,5-trifluoro-phenyl)-1H-benzoimidazol-2-yl]-piperazin-1-yl}-5-trifluoromethyl-pyridin-3-yl)-methanol 
• 683244-36-2 (R)-6-(3-methyl-4-(6-(trifluoromethyl)-4-(3,4,5-trifluorophenyl)-1H-benzo[d]imidazol-2-yl)piperazin-1-yl)-5-(trifluoromethyl)nicotinaldehyde 
• 900184-24-9 (R)-2-(5-chloro-6-(4-(4-(4-fluorophenyl)-6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-3-methylpiperazin-1-yl)pyridin-3-ylamino)-2-oxoethyl acetate 
• 683244-22-6 5-chloro-6-{3-methyl-4-[6-trifluoromethyl-4-(3,4,5-trifluoro-phenyl)-1H-benzoimidazol-2-yl]-piperazin-1-yl}-nicotinic acid methyl ester 
• 683243-45-0 6-(trifluoromethyl)-4-(4-(trifluoromethyl)cyclohex-1-enyl)-2-(4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-1H-benzo[d]imidazole 
• 900184-35-2 2-[4-(3-chloro-5-vinyl-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-trifluoromethyl-4-(3,4,5-trifluoro-phenyl)-1H-benzoimidazole 
• 900184-18-1 2-[4-(5-bromo-3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-trifluoromethyl-4-(3,4,5-trifluoro-phenyl)-1H-benzoimidazole 
• 683242-24-2 6-trifluoromethyl-2-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-4-(3,4,5-trifluorophenyl)-1H-benzoimidazole 

Relevant academic research and scientific papers

Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H- benzimidazoles

The vanilloid receptor-1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2- ylpiperazin-1-yl)-1H-benzo-[d]imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant (CFA).

AMINOCYCLOPENTYL FUSED HETEROTRICYLICAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of formulae (I and II) (wherein A, D, E. X, l, m, n and R through R are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modul

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.